Bivatuzumab

• CAT Number: I042426
• CAS Number: 214559-60-1
• Purity: ≥95%

Bivatuzumab (Cat No.: I042426) is a humanized monoclonal antibody that specifically targets CD44v6, an isoform of the CD44 cell surface glycoprotein overexpressed in various epithelial cancers, including head and neck squamous cell carcinoma. By binding to CD44v6, Bivatuzumab enables targeted delivery of therapeutic agents, such as radioisotopes or cytotoxins, enhancing selective tumor cell destruction while sparing normal tissue. It has been explored in antibody-drug conjugate (ADC) and radioimmunotherapy formats, offering a promising strategy for precision oncology in CD44v6-positive tumors.

Reference

[1]. Leuci V,et al. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology. 2018 Feb 15;7(5):e1423167.
[Content Brief]